Research programme: SCF ubiquitin ligase complex inhibitors - Rigel
Latest Information Update: 26 Aug 2010
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Ubiquitin-protein ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Mar 2007 Preclinical trials in Cancer in USA (unspecified route)